Lilly Alzheimer’s drug shows benefit on cognition, function in mid stage trial
over 4 years in nationalpost
Eli Lilly and Co on Saturday said its experimental Alzheimer’s drug slowed the rate of decline in a measure of cognition and function by 32% compared with a placebo in a mid-stage trial of patients at an early stage of the mind wasting disease. The drug, donanemab, also showed positive trends that failed to reach […]
Who is popular today?
